Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
. Keywords: ; ; ; ; 1 Introduction Irritablebowelsyndrome (IBS) is one of the most frequent digestive tract disorders, which is encountered by general practitioners and gastroenterologists. It is a functional disorder of the digestive tract, which causes chronic symptoms, such as abdominal pain and discomfort and abnormal bowel movements, including diarrhea and constipation, with no organic abnormalities. Prevalence of IBS varies between Asian and North American societies, but the total range (...) of vitamin D in reducing gastrointestinaldisease risk and assessment of individual dietary intake needs: focus on genetic and genomic technologies. Mol Nutr Food Res. 2016;60:119-133. 29 Martínez C, González-Castro A, Vicario M, Santos J. Cellular and molecular basis of intestinal barrier dysfunction in the irritablebowelsyndrome. Gut Liver. 2012;6:305-315. 30 Major G, Spiller R. Irritablebowelsyndrome, inflammatory boweldisease and the microbiome. Curr Opin Endocrinol Diabetes Obes. 2014;21:15-21
PWE-076 Efficacy of Pharmacological Therapies in Patients with IrritableBowelSyndrome with Diarrhoea: Network Meta-analysis PWE-076 Efficacy of Pharmacological Therapies in Patients with IrritableBowelSyndrome with Diarrhoea: Network Meta-analysis | Gut Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here PWE-076 Efficacy of Pharmacological Therapies in Patients with IrritableBowelSyndrome with Diarrhoea: Network Meta-analysis Article Text Posters PWE-076 Efficacy of Pharmacological Therapies in Patients with IrritableBowelSyndrome with Diarrhoea: Network Meta-analysis Free Christopher Black , , Nicholas Burr , , Michael Camilleri , David Earnest , Eamonn Quigley , Paul
Division of Gastroenterology, University of T oronto, T oronto, Ontario, Canada; 10 Division of Gastroenterology, Queen’s University, Kingston, Ontario, Canada Correspondence: Dr. Paul Moayyedi, BSc, MB, ChB, PhD, MPH, FRCP , FRCPC, AGAF, FACG, Director, Division of Gastroenterology, McMaster University, 1280 Main St. W . HSC 3V3, Hamilton, ON, Canada L8S 4K1, E-mail: firstname.lastname@example.org ABSTRACT Background & aims: Irritablebowelsyndrome (IBS) is one of the most common gastrointestinal (GI) disorders (...) /gwy071 Original Article Downloaded from https://academic.oup.com/jcag/advance-article-abstract/doi/10.1093/jcag/gwy071/5290372 by guest on 22 January 2019Irritable bowelsyndrome (IBS) is one of the most common gastrointestinal (GI) disorders. It is characterized by recurrent abdominal pain and altered bowel habits (i.e., constipation, diarrhea or both), often with associated bloating (1). Globally, IBS is estimated to affect about 10% of the general population, but prevalence rates are highly
]; Irritablebowelsyndrome; Colonicdiseases, functional; Evidence-based medicine; Evidence-based practice INTRODUCTION Irritablebowelsyndrome (IBS) is a frequent clinical disorder. Its prevalence has been estimated as 11% worldwide, with a range from 3% to 15% according to the diagnostic criteria used. The definition most commonly used is the one that was proposed by the Rome IV investigators, and this takes into account recurrent abdominal pain associated with other gastrointestinal symptoms, without (...) Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. VI MD, MSc, PhD. Rheumatologist and Adjunct Professor, Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), and Researcher, Cochrane Brazil, São Paulo (SP), Brazil. BACKGROUND: Irritablebowelsyndrome (IBS) is a clinical disorder associated with high socioeconomic burden. Despite its importance, management of IBS remains difficult and several interventions
be individualised and is dependent on the patient's predominant symptoms. Definition Irritablebowelsyndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune (...) , psychological, and dietary components. Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritablebowelsyndrome. Gastroenterology. 2002 Dec;123(6):2108-31. http://www.ncbi.nlm.nih.gov/pubmed/12454866?tool=bestpractice.com History and exam presence of risk factors abdominal discomfort alteration of bowel habits associated with pain abdominal bloating or distension normal examination of abdomen passage of mucus with stool physical and sexual abuse age <50 years female sex previous enteric
and management [ ] and expert opinion in review articles on irritablebowelsyndrome [ ; ; ; ] and review articles on the Rome IV criteria for functional gastrointestinaldisorders [ ; ]. CKS notes that the Rome IV criteria for the diagnosis of functional gastrointestinaldisorders (which are predominantly used for clinical trials and research) have amended the criteria used to diagnose IBS [ ; ]. The term abdominal 'discomfort' is no longer included as a diagnostic criterion, as this is a non-specific term (...) Irritablebowelsyndrome: When should I suspect irritablebowelsyndrome? Diagnosis | Diagnosis | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Diagnosis Irritablebowelsyndrome: When should I suspect irritablebowelsyndrome? Last revised in October 2017 When should I suspect irritablebowelsyndrome? Consider the diagnosis of irritablebowelsyndrome (IBS) in a person who has had any of the following symptoms for at least 6 months: Abdominal pain, or Bloating, or Change in bowel
Irritablebowelsyndrome: What else might it be? Differential diagnosis | Diagnosis | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Differential diagnosis Irritablebowelsyndrome: What else might it be? Last revised in October 2017 What else might it be? Alternative conditions which may present similarly to irritablebowelsyndrome include: Malignancy (such as colorectal cancer, small bowel cancer, and lymphoma) — see the CKS topic on for more information. Other causes (...) of constipation, such as: Functional or drug-induced constipation — see the CKS topic on for more information. Hypothyroidism — see the CKS topic on for more information. Other causes of diarrhoea, such as: Inflammatory boweldisease — see the CKS topics on and for more information. Coeliac disease — see the CKS topic on for more information. Gastrointestinal infection and secondary lactose intolerance — see the CKS topic on for more information. Antibiotic-associated diarrhoea (for example Clostridium
Irritablebowelsyndrome: Loperamide Loperamide | Prescribing information | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Loperamide Irritablebowelsyndrome: Loperamide Last revised in October 2017 Loperamide Loperamide is licensed for the symptomatic treatment of acute diarrhoea in irritablebowelsyndrome (IBS). The recommended dose is: Initially 4 mg, followed by 2 mg for up to five days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day (...) . [ ] Contraindications and cautions Do not prescribe loperamide if the person has: Acute ulcerative colitis. Antibiotic-associated colitis. Conditions where abdominal distention develops. Conditions where inhibition of peristalsis should be avoided. Prescribe loperamide with caution if the person has: Hepatic impairment — due to reduced first-pass metabolism and the risk of hepatic accumulation. [ ] Adverse effects Possible adverse effects of loperamide include: Dizziness, headaches, flatulence, nausea. Abdominal
Irritablebowelsyndrome: Linaclotide Linaclotide | Prescribing information | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Linaclotide Irritablebowelsyndrome: Linaclotide Last revised in October 2017 Linaclotide Linaclotide 290 microgram capsules should be taken once daily, the dose to be taken at least 30 minutes before meals. [ ] Contraindications and cautions Do not prescribe linaclotide if there is suspected: Intestinal obstruction. Crohn's disease or ulcerative colitis (...) . Prescribe linaclotide with caution if there is: A predisposition to fluid and electrolyte disturbance. An increased risk of diarrhoea, for example with co-prescribing of nonsteroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors. [ ] Adverse effects Possible adverse effects of linaclotide include: Abdominal distention, abdominal pain, diarrhoea, dizziness, flatulence. If diarrhoea is severe or prolonged, consider stopping treatment. Decreased appetite, dehydration, faecal incontinence
syndrome [ ; ; ; ] and a review article on the Rome IV criteria for functional gastrointestinaldisorders [ ]. An assessment of the person's bowel habit and stool type will determine whether the person has diarrhoea-predominant, constipation-predominant, or mixed irritablebowelsyndrome symptoms. This allows management to be targeted to the different sub-types [ ]. An assessment of psychosocial stressors or co-morbidity is important, as initial presentations and exacerbations of IBS symptoms are often (...) Irritablebowelsyndrome: How should I assess a person with suspected irritablebowelsyndrome? Assessment | Diagnosis | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Assessment Irritablebowelsyndrome: How should I assess a person with suspected irritablebowelsyndrome? Last revised in October 2017 How should I assess a person with suspected irritablebowelsyndrome? If a diagnosis of irritablebowelsyndrome (IBS) is , assess the person's clinical features: Ask about: The type
be individualized to the person's symptoms and psychosocial situation, and should initially include diet and lifestyle advice. Provide advice and reassurance about the diagnosis of irritablebowelsyndrome, and offer sources of information and support, such as: The NHS patient leaflet . The gut and liver disease charity CORE (website available at ) provides support for patients and families and has a patient information leaflet . The IBS Network is a national charity supporting people living with irritable (...) physical activity, and encourage weight loss if the person is overweight or obese. See the CKS topic on for more information. Adults should aim to do 30 minutes of moderate intensity physical activity on at least 5 days of the week. Arrange to review the person, depending on clinical judgement, and if there are ongoing or refractory symptoms, consider further management options such as . Basis for recommendation The recommendations on the initial management of irritablebowelsyndrome is largely based
Irritablebowelsyndrome: Bulk-forming laxatives Bulk-forming laxatives | Prescribing information | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Bulk-forming laxatives Irritablebowelsyndrome: Bulk-forming laxatives Last revised in October 2017 Bulk-forming laxatives Bulk-forming laxatives (containing soluble fibre) act by retaining fluid within the stool and increasing faecal mass, stimulating peristalsis; also have stool-softening properties. Ispaghula husk (also known as psyllium (...) before bed. Adequate fluid intake is important, to prevent intestinal obstruction. Tablets swell in the mouth on contact with water. Typically takes 2–3 days to take effect. [ ; ; ] Contraindications and cautions Do not prescribe laxatives if there is suspected: Intestinal obstruction or perforation. Paralytic ileus. Colonic atony or faecal impaction (bulk-forming laxatives). Crohn's disease or ulcerative colitis. Toxic megacolon. Prescribe laxatives with caution if there is: Fluid and electrolyte
Irritablebowelsyndrome: Antispasmodic drugs Antispasmodic drugs | Prescribing information | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Antispasmodic drugs Irritablebowelsyndrome: Antispasmodic drugs Last revised in October 2017 Antispasmodic drugs Antispasmodic drugs may be used as required for abdominal pain or spasm in irritablebowelsyndrome (IBS). Drug options include: Direct-acting smooth muscle relaxants such as mebeverine hydrochloride (immediate-release or modified (...) for up to 2–3 months if needed, dose to be taken before meals, swallowed whole with water. [ ] Contraindications and cautions Do not prescribe direct-acting smooth muscle relaxants (such as mebeverine hydrochloride or alverine citrate) to people with: Intestinal obstruction. Paralytic ileus. Prescribe peppermint oil with caution to people with: Sensitivity to menthol. [ ] Adverse effects Possible adverse effects of: Alverine citrate include dizziness, dyspnoea, headache, hepatitis, jaundice (resolves
Irritablebowelsyndrome: Antidepressant drugs Antidepressant drugs | Prescribing information | Irritablebowelsyndrome | CKS | NICE Search CKS… Menu Antidepressant drugs Irritablebowelsyndrome: Antidepressant drugs Last revised in October 2017 Antidepressant drugs Tricyclic antidepressants (TCAs) such as amitriptyline, may be used for the management of pain associated with irritablebowelsyndrome (off-label indication). The National Institute for Health and Care Excellence (NICE (...) therapy. Diabetes mellitus. Epilepsy — stop treatment if seizures develop. History of bleeding disorders, especially gastrointestinal bleeding. Susceptibility to angle-closure glaucoma. Susceptibility to QT interval prolongation (citalopram only). [ ] Adverse effects Possible adverse effects of amitriptyline include: Abdominal pain, fatigue, hypertension, mydriasis, oedema, palpitations, restlessness, stomatitis. Dysarthria, extrapyramidal symptoms, tremor, paralytic ileus. Possible adverse effects
Regul8 for adults with irritablebowelsyndrome Regul8 for adults with irritablebowelsyndrome 18 October 2019 Summary • The technology described in this briefing is Regul8. It is an online cognitive behavioural therapy (CBT) programme designed to treat irritablebowelsyndrome (IBS). • The scope for this briefing is to consider the use of Regul8 to treat IBS in a therapist-guided model of care, in adult Improving Access to Psychological Therapies (IAPT) services, for the NHS England (...) and depression. IAPT services offer evidence-based psychological therapies given by accredited practitioners, with routine monitoring and regular outcomes-focused supervision. The care pathway for IBS is described in the NICE guideline on irritablebowelsyndrome in adults. NICE recommends referral for psychological interventions (CBT, hypnotherapy and/or psychological therapy) to be considered for people with IBS who do not respond to pharmacological treatments after 12 months and who develop a continuing
Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for IrritableBowelSyndrome: 12-Month Follow-Up There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 (...) with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritablebowelsyndrome More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritablebowelsyndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric (...) infection.Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the IrritableBowelSyndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8
Faecal microbiota transplantation alters gut microbiota in patients with irritablebowelsyndrome: results from a randomised, double-blind placebo-controlled study IBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients
on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com Top results for irritablebowelsyndrome 1. Probiotics for irritablebowelsyndrome 2017 2. IrritablebowelsyndromeIrritablebowelsyndrome - NICE CKS Clinical Knowledge Summaries Share Irritablebowelsyndrome - Summary Irritablebowelsyndrome ( IBS ) is a chronic, relapsing, and often lifelong disorder of gastrointestinal function (...) of irritablebowelsyndrome Poynard T, Regimbeau C, Benhamou Y Authors' objectives To assess the efficacy and tolerance of smooth muscle relaxants in the treatment of irritablebowelsyndrome ( IBS ). Searching A search of MEDLINE and a manual search were combined (...) . The keywords used were 'colonicdisease ', 'functional', irritablebowelsyndrome ' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents